Abyssinia is altering the world's understanding of Alzheimer's Disease from diagnostic assays with the potential for early diagnosis to treatment approaches addressing novel disease causes. Abyssinia's lead candidate ABY-71A1 is a IgG1 mAb with a high specificity for toxic soluble amyloid oligomers, which is backed up by ourcompanion diagnostic assay for soluble amyloid in plasma & CSF. Abyssinia was founded in 2017.

Biotechnology

Abyssinia Biologics

Abyssinia Biologics' headquarters in Portsmouth, NH, United States

Trebor R. Lawton

Paul Treacy

Guriq Basi

Saira Ramasastry

Eric Yuen Md

Larry Jasinksi

Robert Lawton

Peter N. Laivins

Enchi Liu

Rajnish Kaushik

Mark Matijevic

Keith Jansen

Larry Jasinski

Michael Papile

Description

People (1)

Trebor R. Lawton

Jobs